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Summary
 
Rel and nuclear factor (NF)-
 
k
 
B1, two members of the Rel/NF-
 
k
 
B transcription factor family,
are essential for mitogen-induced B cell proliferation. Using mice with inactivated Rel or NF-
 
k
 
B1
genes, we show that these transcription factors differentially regulate cell cycle progression and
apoptosis in B lymphocytes. Consistent with an increased rate of mature B cell turnover in naive
 
nfkb1
 
2
 
/
 
2
 
 mice, the level of apoptosis in cultures of quiescent nfkb1
 
2
 
/
 
2
 
, but not c-rel
 
2
 
/
 
2
 
, B
cells is higher. The failure of c-rel
 
2
 
/
 
2
 
 or nfkb1
 
2
 
/
 
2
 
 B cells to proliferate in response to particular
mitogens coincides with a cell cycle block early in G1 and elevated cell death. Expression of a bcl-2
transgene prevents apoptosis in resting and activated c-rel
 
2
 
/
 
2
 
 and nfkb1
 
2
 
/
 
2
 
 B cells, but does
not overcome the block in cell cycle progression, suggesting that the impaired proliferation is not
simply a consequence of apoptosis and that Rel/NF-
 
k
 
B proteins regulate cell survival and cell cycle
control through independent mechanisms. In contrast to certain B lymphoma cell lines in which
mitogen-induced cell death can result from Rel/NF-
 
k
 
B–dependent downregulation of c-myc,
expression of c-myc is normal in resting and stimulated c-rel
 
2
 
/
 
2
 
 B cells, indicating that target
gene(s) regulated by Rel that are important for preventing apoptosis may differ in normal and
immortalized B cells. Collectively, these results are the first to demonstrate that in normal B cells,
NF-
 
k
 
B1 regulates survival of cells in G0, whereas mitogenic activation induced by distinct stimuli
requires different Rel/NF-
 
k
 
B factors to control cell cycle progression and prevent apoptosis.
 
T
 
he outcome of lymphocyte responses to antigenic or
mitogenic activation reflects a balance between the
 
relative rates of cell division, death, and differentiation (1).
Although signal transduction pathways that control cell
survival and proliferation are the subject of intense investi-
gation, in mature B cells little is known about the role of
transcription factors in regulating these processes. Among
the many transcription factors implicated in controlling gene
expression in B lymphocytes (2), the Rel (3) and nuclear
factor (NF)-
 
k
 
B1 (4, 5) subunits of the Rel/NF-
 
k
 
B family
have recently been shown to be essential for mitogen-induced
proliferation. Rel/NF-
 
k
 
B transcription factors are homo-
and heterodimeric proteins comprising subunits encoded
by a small multigene family related to the 
 
c-rel
 
 protoonco-
gene (6). These proteins regulate transcription by binding
to decameric sequences (
 
k
 
B motifs) located in the promot-
ers and enhancers of many viral and cellular genes, particu-
larly those encoding proteins involved in immune, acute
phase, and inflammatory responses (6–8). The five known
mammalian Rel/NF-
 
k
 
B proteins, NF-
 
k
 
B1 (p50, p105),
NF-
 
k
 
B2 (p52, p100), RelA (p65), RelB, and Rel share a
highly conserved 300–amino acid NH
 
2
 
-terminal Rel ho-
mology domain that encompasses sequences required for
DNA binding, protein dimerization, and nuclear localiza-
tion (6). The CH
 
2
 
-termini of these proteins are divergent,
with those of Rel, RelA, and RelB containing transcrip-
tional transactivation domains (6, 9). Before stimulation, in
most cells, a large proportion of Rel/NF-
 
k
 
B is retained in
the cytoplasm in an inactive form through association with
a family of inhibitor (I
 
k
 
B) proteins (10, 11). A wide range
of stimuli promote the nuclear translocation of Rel/NF-
 
k
 
B
complexes by a mechanism involving the phosphorylation
of conserved NH
 
2
 
-terminal serine residues in I
 
k
 
B
 
a
 
 and
I
 
k
 
B
 
b
 
 (12, 13), which targets these I
 
k
 
B proteins for ubiq-
uitin-dependent proteosome-mediated degradation (12–15).
To determine the physiological roles of the various Rel/
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k
 
B
 
NF-
 
k
 
B proteins, mice with inactivated 
 
c-rel
 
 (3), 
 
nfkb1
 
 (4),
 
relb
 
 (16, 17), or 
 
rela
 
 (18) genes have been generated by gene
targeting. rela
 
2
 
/
 
2
 
 mice die at day 15 of embryogenesis, ap-
parently as a result of fetal hepatocyte apoptosis (18). In
contrast, Rel (3), RelB (16, 17), and NF-
 
k
 
B1 (4) are not
essential for embryogenesis, but are important in the func-
tion of hemopoietic cells. Although differentiation of stem
cells into all hemopoietic lineages appears normal in c-rel
 
2
 
/
 
2
 
and nfkb1
 
2
 
/
 
2
 
 mice, Rel and NF-
 
k
 
B1 are involved in con-
trolling genes induced during immune responses. Mature B
cells from both mutant strains are defective in their re-
sponse to mitogens and antigens (3, 4), whereas T cells and
macrophages from c-rel
 
2
 
/
 
2
 
 mice exhibit defects in the pro-
duction of cytokines and immune regulatory molecules, in-
cluding IL-2, IL-3, IL-6, GM-CSF, G-CSF, TNF-
 
a
 
, and
iNOS (19, 20). RelB appears to serve a dual role. Naive
RelB
 
2
 
/
 
2
 
 mice spontaneously develop hemopoietic lesions
characterized by multifocal inflammatory infiltrates, mye-
loid hyperplasia, and splenomegaly (16, 17). Although this
phenotype suggests that RelB is important in regulating
genes in hemopoeitic cells that are associated with constitu-
tive or housekeeping functions, RelB
 
2
 
/
 
2
 
 mice challenged
with pathogens reveal that RelB is also involved in various
specific and nonspecific immune responses (17).
Rel/NF-
 
k
 
B proteins have also been implicated in the
control of apoptosis. For example, loss of RelA renders
embryonic fibroblasts highly sensitive to TNF-
 
a
 
–induced
apoptosis (21) and expression of a 
 
trans
 
-dominant I
 
k
 
B
 
a
 
mutant in various cell types markedly increases the death of
these cells when treated with TNF-
 
a
 
, ionizing radiation,
or daudorubicin (22, 23). Although enforced expression of
Rel can overcome TNF-
 
a
 
–induced apoptosis of HeLa cells
expressing the 
 
trans
 
-dominant I
 
k
 
B
 
a
 
 mutant (24), Rel has
also been implicated as an inducer of cell death. Overex-
pression of Rel induces apoptosis in chicken bone marrow
cells (25) and high levels of c-rel messenger RNA (mRNA)
 
1
 
were found in cells undergoing programmed cell death in
the developing chick embryo (25).
Although Rel and NF-
 
k
 
B1 have been shown to be im-
portant in mitogen-induced B cell proliferation (3, 4), it is
not known whether these proteins are needed for cell cycle
progression, inhibition of apoptosis, or both. Here we ex-
amine in detail defects in proliferation and cell survival of B
cells from c-rel
 
2
 
/
 
2
 
 and nfkb1
 
2
 
/
 
2
 
 mice. The results show
that different mitogenic signals require Rel and/or NF-
 
k
 
B1 to promote G1 progression during B cell division and
that specific NF-
 
k
 
B–like factors are necessary for the sur-
vival of quiescent and mitogen activated B cells.
 
Materials and Methods
 
Mice.
 
The generation of the c-rel
 
2
 
/
 
2
 
 (3) and nfkb1
 
2
 
/
 
2
 
 (4)
mice and E
 
m
 
-bcl-2-36 transgenic mice, which express a human
bcl-2 cDNA in B and T cells (26), has been described previously.
 
All mouse strains had been backcrossed for 
 
.
 
9 generations with
C57BL/6 mice before being used for this study. c-rel
 
2
 
/
 
2
 
bcl-2
 
1
 
and nfkb1
 
2
 
/
 
2
 
bcl-2
 
1
 
 mice were generated by intercrossing the
two parental mouse strains. Inheritance of the 
 
c-rel
 
 and 
 
nfkb1
 
 mu-
tant alleles and the bcl-2 transgene was determined by PCR anal-
ysis of tail biopsy DNA samples using specific oligonucleotide
primers.
Purification of B Lymphocytes. Small, resting B lymphocytes
were purified from spleens of 4–6-wk-old wild-type c-rel2/2,
c-rel1/2, or nfkb12/2 litter-matched mice by negative cell sort-
ing. In brief, all unwanted cells (granulocytes, macrophages,
erythroid cells, and T lymphocytes) were stained with FITC-
labeled surface marker specific monoclonal antibodies (8C5 anti-
Gr-1, M1/70 anti-Mac-1, Ter119, T24.31.2 anti-Thy1, KT3 anti-
CD3, GK1.5 anti-CD4, and 53.6.72 anti-CD8) and dead cells
were stained with the vital dye propidium iodide (PI; 1 mg/ml).
Viable cells that were not stained with the FITC-labeled mono-
clonal antibodies were purified on a FACSÒ II or a FACStar
PlusÒ cell sorter (Becton Dickinson, San Jose, CA). The purity of
all sorted B cells was verified by staining cells with a phycoerthy-
rin labeled anti-B220 antibody (CALTAG Labs., S. San Fran-
cisco, CA) and ranged between 97 and 99% purity.
B Lymphocyte Activation in Tissue Culture. B lymphocytes were
cultured in the high glucose version of DMEM supplemented
with 13 mM folic acid, 250 mM l-asparagine, 50 mM 2-mercap-
toethanol, and 10% fetal bovine serum at an initial concentration
of 3 3 105/ml. Cells were stimulated in vitro with LPS (Difco,
Detroit, MI) at a concentration of 20 mg/ml, affinity purified goat
anti–mouse IgM (Fab9)2 fragments (Jackson Immuno Research,
Bar Harbor, ME) at 20 mg/ml, rat anti–mouse CD40 monoclonal
antibody FGK45 (a gift of Dr A. Rolink, Basel Institute, Basel,
Switzerland) at 2 mg/ml, or rat anti–mouse RP monoclonal anti-
body at 1 mg/ml (27). All stimulations were performed in the ab-
sence or presence of saturating concentrations of recombinant
mouse interleukins, IL-2, IL-4, and IL-5.
Cell Turnover Studies. Cell turnover was determined by label-
ing proliferating cells in vivo with the thymidine analogue 5-bro-
mo-29-deoxyuridine (BrdU; Sigma Chemical Co., St. Louis,
MO), which was provided continuously for 1, 3, or 7 d in the
drinking water (1 mg/ml plus 2% glucose to overcome taste aver-
sion). Drinking water bottles were shielded from light and ex-
changed after 3 days. Spleen cellularity did not alter significantly
during the course of this treatment. BrdU incorporated into cel-
lular DNA was detected by immunofluorescence staining with an
FITC-labeled monoclonal antibody BU-1 (Becton Dickinson)
and flow cytometric analysis performed according to published
procedures (28). In brief, cells were fixed in 0.5% paraformalde-
hyde in PBS (20 min at room temperature). As the BU-1 anti-
body only binds to BrdU within single-stranded DNA, the DNA
was denatured using 3N HCl containing 0.5% Tween-20 to per-
meabilize cell membranes (20 min at room temperature). The
acid was neutralized with 0.1 M disodiumtetraborate and cells
were then stained (30 min) with FITC–BU-1 in the presence of
0.5% Tween-20. Combined analysis of incorporated BrdU and
cell surface antigen expression to identify virgin and mature B
cells was performed using a modified version of published proce-
dures (28). R-PE anti-IgM (CALTAG Labs.) and biotinylated
anti-IgD (clone 11-26C) antibodies plus Tricolor-streptavidin
(CALTAG Labs.) were used to identify virgin B cells (IgM1IgD2)
and mature B cells (IgM1IgD1). Cells were stained with biotiny-
lated antibodies and fluorochrome conjugates after fixation and
DNA denaturation with the exception of biotinylated anti-IgD,
which had to be added beforehand. Flow cytometric analysis
1Abbreviations used in this paper: BrdU, 5-bromo-2-deoxyuridine; mRNA,
messenger RNA; PI, propidium iodide.665 Grumont et al.
(10,000 cells/sample) was performed on a FACScanÒ. As a nega-
tive control for staining with FITC–BU-1 anti-BrdU antibody,
we included cells from a mouse that had not received BrdU in
the drinking water in all experiments. Routinely, ,1% of such
cells were stained above background. To verify that mice had in-
corporated BrdU and as a positive control for staining with
FITC-BU-1, we routinely confirmed that cells with a high turn-
over rate, such as granulocytes within bone marrow, were
strongly labeled.
Proliferation and RNA Synthesis Assays. B cells were cultured
as described above in 100 ml at a starting density of 3 3 105 cells/ml
in 96-well microtiter plates. Cellular proliferation and RNA syn-
thesis were measured at various times by adding 0.5 mCi of
[3H]thymidine or 0.25 mCi of [3H]uridine, respectively, for 6 h,
after which cells were harvested onto glass fiber filters. Incorpo-
rated radioactivity was quantitated by scintillation counting.
Immunofluorescence Staining and Flow Cytometry. The expression
of class II MHC, B7.2, and CD25 was analyzed on resting and
anti-IgM– or anti-CD40–treated splenic B cells were stimulated
for 24 h. Cells were surface stained with biotinylated monoclonal
antibodies M5/114 (anti-class II MHC), GL-1 (anti-B7.2), PC16
(anti–IL-2 receptor a chain CD25), or isotype-matched control
monoclonal antibodies as described previously (3). Binding of bi-
otinylated antibodies was revealed by staining with R-phyco-
erythrin-streptavidin (CALTAG Labs.) as the secondary reagent.
Viable (PI negative) cells (5,000–10,000) were analyzed in a FACS-
canÒ flow cytometer (Becton Dickinson). For the coculture ex-
periments, c-rel2/2 (Ly5.1) cells were separated from control c-rel1/1
(Ly5.2) cells by cell sorting after staining with a biotinylated anti-
Ly5.2 monoclonal antibody plus R-PE streptavidin.
Cell Cycle Analysis. Cell division in mitogen stimulated lym-
phocyte cultures was determined by assessing cellular DNA con-
tent using PI staining (29). Cells were first fixed (.8 h at 48C) in
70% ethanol, treated with 0.5 mg/ml DNase-free RNase A (Boeh-
ringer Mannheim, Indianapolis, IN) for 20 min at room tempera-
ture, and finally stained with 69 mM PI in 0.1 M sodium citrate
(pH 7.4) for 30 min at 48C. Flow cytometric analysis (10,000
cells/sample) was performed on a FACScanÒ at a low flow rate
(100–300 cells/s). Cell cycle distribution was determined with
the Cellfit program (Becton Dickinson) or manual gating.
Analysis of DNA and Protein Content. Simultaneous analysis of
cellular DNA and protein content was performed as described
previously (30). In brief, 5 3 105 resting or mitogen-activated B
cells were first fixed in ice-cold 70% ethanol (.8 h), washed once
in phosphate-buffered saline, and resuspended at a cell density of
z106 cells/ml in PBS containing 0.5 mg/ml Hoechst 33342
(HO; Calbiochem Corp., La Jolla, CA), 1 mg/ml pyronin Y
(Polysciences, Warrington, PA), and 0.1 mg/ml FITC (isomer 1;
BBL Microbiology Systems, Cockeyville, MD). Cells were
stained for 30 min and then analyzed by flow cytometry using a
modified dual lasar FACSÒ II. Dead cells were excluded from
analyses by gating on forward and side light scatter parameters. A
total of 10,000 events were collected and analyzed using an in
house computer program.
Northern Blot Analysis. 10 mg samples of total RNA isolated
from resting or anti-IgM antibody-activated B cells were frac-
tionated on 1% formaldehyde agarose gels, transferred onto Hy-
bond C Extra (Amersham Corp., Arlington Heights, IL) and
sequentially hybridized as previously described (31) with a 32P-
radiolabeled mouse 1.4-kb XhoI c-myc cDNA (32) and a rat 1.1kb
PstI glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) cDNA
(33). Both probes were labeled by random primer extension to
specific activities ranging between 5 3 108 and 109 cpm/mg.
Results
Apoptosis of Quiescent B Cells Is Accelerated by the Loss of
NF-kB1, but Not by an Absence of Rel. To assess whether
Rel and NF-kB1 have a role in regulating the survival of
primary B cells, we first compared the rate of B cell turn-
over in normal, c-rel2/2 and nfkb12/2 mice. Splenic B
cells isolated from mice administered BrdU in the drinking
water continuously for up to 7 d were analyzed for BrdU
incorporation using flow cytometry (Fig. 1 A). Although
no significant difference was observed in the rate of BrdU
incorporated by surface (s)IgM1sIgD2 or sIgM1sIgD1 splenic
B cells after 2 d, by days 4 and 7 of this kinetic analysis,
nfkb12/2 B cells had incorporated between two- and four-
fold more BrdU than either normal or c-rel2/2 B cells. To
determine if the increased turnover of nfkb12/2 B cells in
vivo could be due to enhanced cell death, the survival of
resting splenic B cells from mice of each strain were exam-
ined in tissue culture (Fig. 1 B). As expected, normal B
cells did not proliferate in the absence of mitogens (results
not shown), and a significant proportion had died by apop-
tosis over the course of 72 h. c-rel2/2 B lymphocytes be-
haved indistinguishably from control cells, whereas the fre-
quency of apoptotic cells was higher in cultures of quiescent
nfkb12/2 B cells. Collectively these findings suggest that
the survival of resting B cells is dependent on NF-kB1, but
not Rel.
Rel and NF-kB1 Are Required for Cell Cycle Progression and
Survival of Mitogen-stimulated B Cells. To determine if the
role of Rel and NF-kB1 in B cell proliferation involves the
regulation of cell division and/or apoptosis, we performed
cell cycle and cell death analysis on mitogen-activated
splenic B cells from c-rel2/2, nfkb12/2, and control mice.
Purified B lymphocytes were stimulated with LPS or cross-
linking antibodies specific for IgM or the B cell–specific
membrane protein, RP (27) in the presence or absence of
cytokines. Cell proliferation and apoptosis were assessed
daily over a 72-h time course by cell counting, [3H]thymi-
dine incorporation, and flow cytometric analysis of cellular
DNA content. The proliferation, apoptosis, and cell divi-
sion data for all mitogenic stimulations is graphically sum-
marized in Fig. 2. The first 24 h of a normal mitogenic re-
sponse is characterized by apoptosis and a low level of cell
division. The extent of cell death is dependent on the stim-
ulus, varying between 15 (LPS) and 44% (anti-IgM anti-
body) (Fig. 2 B). Between 24 and 72 h, a reduction in the
frequency of dead cells coincides with an increase in viable
cells due to division (Fig. 2, A and C; [3H]thymidine incor-
poration and the frequency of cells residing in S, and G2/M,
respectively). Consistent with previous findings, c-rel2/2 (3)
and nfkb12/2 (4, 5) B cells exhibit overlapping, but distinct,
defects in mitogen responsiveness. c-rel2/2 B cells prolif-
erate poorly in response to all single mitogens, whereas
nfkb12/2 B cells react normally to anti-IgM antibody, but
show diminished (10-fold) responsiveness to anti-RP anti-
body and respond poorly to LPS (3–5% of normal [3H]thy-
midine incorporation). A combination of the cytokines IL-2,
IL-4, and IL-5, which alone do not induce B cell prolifera-666 Regulation of Apoptosis and Cell Division in B Cells by Rel/NF-kB
tion, but instead maximize the response of normal B cells
to mitogens (34), only rescued some c-rel2/2 and nfkb12/2
B cell mitogenic responses such as the anti-RP antibody
stimulation of Rel2/2 cells.
Impaired c-rel2/2 and nfkb12/2 B cell proliferation co-
incides with higher than normal levels of apoptosis (Fig. 2
B) and reduced cell division (Fig. 2 C), the extent of which
both vary in a mitogen-specific manner. For example, after
72 h, 93 and 60% of anti-IgM– and anti-RP–stimulated
c-rel2/2 cells, respectively, have undergone apoptosis com-
pared to 20 and 18% of normal B cells. Of the remaining
viable B cells, ,0.5% of anti-IgM or anti-RP antibody-
stimulated c-rel2/2 cells are in S or G2/M (compared with
30 and 37% of normal cells). LPS stimulation leads to the
death of 34 and 44% of c-rel2/2 and nfkb12/2 B cells, re-
spectively, after 72 h (compared with 11% of normal cells),
with 10- and 6-fold fewer of the viable c-rel2/2 (3.5%) and
nfkb12/2 (5.5%) cells, respectively, residing in S or G2/M
compared to normal B cells (35%). Cytokines enhance pro-
liferation of c-rel2/2 and nfkb12/2 B cells by increasing cell
division and reducing apoptosis (see Fig. 2 C). 
Increased Apoptosis and Impaired Division of Mitogen-stimu-
lated c-rel2/2 B Lymphocytes Is Cell Autonomous. As previ-
ous studies have demonstrated that Rel is a crucial regula-
tor of several growth factor and cytokine genes (3, 19, 20),
we determined if the impaired cell division and increased
apoptosis of mitogen-stimulated c-rel2/2 B cells resulted
from an inability to produce an autocrine growth factor or
the expression of a growth inhibitory activity. This was as-
sessed by comparing apoptosis and cell cycle progression in
anti-IgM or anti-RP antibody-stimulated cocultures of
Ly5.1 c-rel2/2 and Ly5.2 c-rel1/1 B cells. The results in
Fig. 3 show that c-rel1/1 and c-rel2/2 cells proliferate or
die by apoptosis at the same rate, regardless of whether the
cells are grown in mixed or separate cultures. Reduced cell
division and increased apoptosis of LPS-stimulated nfkb12/2
B cells was also shown not to be influenced by the presence
of normal cells (Grumont, R.J., results not shown). These
Figure 1. The absence of NF-
kB1 accelerates apoptosis of qui-
escent B cells. (A) B cells turnover
more rapidly in nfkb12/2 mice.
The turnover of virgin and ma-
ture splenic B cells was determined
by BrdU incorporation. Splenic
B cells isolated from normal,
c-rel2/2, and nfkb12/2 mice fed
with BrdU for 2, 4, or 7 d were
subjected to three-color immuno-
fluorescence staining, after which
flow cytometric analysis was used
to identify virgin (sIgM1sIgD2)
and mature (sIgM1sIgD1) B cells
and to determine the fraction of
these cells that had incorporated
BrdU. Examples from the analysis of mice fed BrdU for 4 d are shown. The top row shows two-color FACSÒ dot plots (x-axis, staining with R-PE–labeled
anti-IgM antibodies; y-axis, staining with biotinylated anti-IgD antibodies plus Tricolor-streptavidin), with the boxed regions used for electronic gating of
mature B cells. The middle rows present histograms of the anti-BrdU–labeling intensity (FITC) of these mature B cells. The percentages of BrdU1 cells
are indicated as are the boundaries used for distinguishing them from BrdU2 cells. The bottom panels summarize the kinetics of BrdU labeling for virgin
and mature splenic B cells over a 4- and 7-d time course, respectively. The values are arithmetic means plus SD from the analysis of three normal, c-rel2/2,
and nfkb12/2 mice at each time point. (B) Cell death in culture. Resting splenic B cells from normal (triangles), c-rel2/2 (circles), and nfkb12/2 (squares)
mice were cultured in DMEM/10% FCS without mitogen for a period of 72 h. At 24-h intervals, the frequency of dead cells was determined by trypan
blue exclusion and flow cytometric analysis of fixed cells stained with PI. At the start of the experiment, .99% of cells of all genotypes were viable. The
data represents the mean 6SD of five experiments.667 Grumont et al.
results establish that the cell cycle block and increased cell
death in mitogen stimulated c-rel2/2 B cell cultures is due
to a cell autonomous defect that does not involve autocrine
growth factors.
Mitogen-stimulated c-rel2/2 B Cells Undergo Some Early Ac-
tivation Steps. Mitogenic activation of B lymphocytes is
associated with early changes in several biochemical and
cellular parameters, including increased cell size, elevated
RNA synthesis, and modified expression of cell surface
proteins (35). We investigated which of the early activation
events are affected by the absence of Rel. Normal and
c-rel2/2 B cells stimulated for 24 h with mitogens and
cytokines were stained with antibodies specific for various
B cell surface markers and then examined by flow cytome-
try. A representative sample of data from cells stimulated
with anti-IgM or anti-CD40 antibodies plus cytokines (IL-2,
IL-4, and IL-5) is shown in Fig. 4. Forward scatter profiles
indicate that although c-rel2/2 B cells enlarge during the
initial 24 h of activation, it is to a lesser extent than normal
B cells. The changes in cell surface marker expression are
complex. B7.2 is upregulated normally on both anti-IgM
and anti-CD40 antibody-stimulated c-rel2/2 cells, but
CD25 expression is only weakly elevated on anti-IgM anti-
body-treated c-rel2/2 cells. This difference appears to be
mitogen-specific, as no significant difference in CD25 in-
duction is seen on anti-CD40 antibody-stimulated normal
or c-rel2/2 cells. MHC class II expression is increased on
c-rel2/2 B cells by mitogen treatment, but to a lesser extent
than on normal B cells. The expression of all other cell surface
markers that were examined on c-rel2/2 lymphocytes was
normal (Strasser, A., results not shown) as were those expressed
on mitogen-stimulated nfkb12/2 B cells (Gerondakis, S.,
unpublished results). These results indicate that c-rel2/2 B
cells can undergo some early events associated with mito-
gen-induced activation, but remain blocked at a stage char-
acterized by a cell volume that is intermediate between the
resting and the cycling state.
The Cell Cycle Block in Mitogen-activated c-rel2/2 and nfkb12/2
B Cells Occurs Early in the G1 State. The low frequency of
Figure 2. Cell cycle progres-
sion is impaired and apoptosis in-
creased in mitogen activated
c-rel2/2 and nfkb12/2 B cells.
Purified, resting normal (trian-
gles), c-rel2/2 (circles), or nfkb12/2
(squares) B cells were stimulated
for 72 h with optimal concentra-
tions of anti-IgM antibodies, LPS,
or anti-RP antibodies in the ab-
sence (open symbols) or presence
(closed symbols) of IL-2, IL-4, and
IL-5. (A) Cellular proliferation.
B cell proliferation was measured
at 24-h intervals over a 72-h pe-
riod by [3H]thymidine incorpo-
ration. (B) Cell death. The fre-
quency of apoptotic cells, expressed
as a proportion of the total cell
number, was determined by flow
cytometric analysis of permeabi-
lized cells stained with PI. Greater
than 99% of resting B cells were
viable at the start of the experi-
ment. (C) Cell cycle analysis.
The fraction of viable B cells in
the S, G2, or M phases of the cell
cycle expressed as a function of
the stimulation period was deter-
mined by flow cytometric analy-
sis of permeabilized cells stained
with PI. Less than 1% of cells
were in G1, S, or G2/M before stimulation. All results in this figure rep-
resent the mean 6SD from eight experiments.
Figure 3. The cell cycle block and enhanced apoptosis in mitogen-
stimulated c-rel2/2 B lymphocytes are due to a cell autonomous defect.
Equivalent numbers of resting c-rel1/1 Ly5.2 (triangles) and c-rel2/2
Ly5.1 (circles) B cells were stimulated separately (open symbols) or in mixed
cultures (closed symbols) with anti-IgM or anti-RP antibodies over a period
of 72 h. At 24-h intervals, normal and Rel2/2 cells from individual cul-
tures or isolated from the mixed cultures by cell sorting were fixed,
stained with PI, and the DNA content determined by flow cytometric
analysis. The frequency of viable normal and c-rel2/2 cells in G0 before
stimulation was .99%. (A) Levels of apoptosis in B cell populations from
the separate or mixed cultures are equivalent. The frequency of apoptotic
cells is expressed as a proportion of the total number of B cells of each
genotype. (B) c-rel2/2 B cell division is not influenced by normal cells.
The percentage of cells in the S plus G2/M phases of the cell cycle corre-
spond to that fraction of the total viable B cell population in each culture.
These results are representative of the mean of four independent experiments.668 Regulation of Apoptosis and Cell Division in B Cells by Rel/NF-kB
anti-IgM or -RP antibody-treated c-rel2/2 and LPS-stimu-
lated nfkb12/2 B cells in S and G2/M indicated that these
cells appear to be blocked at an earlier point in the cell pro-
liferative cycle. Although the partial enlargement of mito-
gen-treated c-rel2/2 B cells was consistent with progression
to an early phase in G1 (36–38), the G1 state can be subdi-
vided into early and late phases; the late phase being char-
acterized by an increased rate of RNA and protein synthesis
(35). To define the point in the cell cycle at which c-rel2/2
and nfkb12/2 B cells arrest, RNA synthesis was monitored
in mitogen-treated B cells by [3H]uridine incorporation.
Fig. 5 A shows that RNA synthesis in anti-IgM antibody,
anti-RP antibody, and LPS-stimulated c-rel2/2 and LPS-
stimulated nfkb12/2 cells is between 10- and 30-fold lower
than in normal cells. Moreover, cytokine enhanced division
of anti-RP antibody-treated c-rel2/2 B cells coincides with
a .20-fold increase in RNA synthesis compared with anti-
RP antibody-stimulated c-rel2/2 B cells. The same trend is
seen in mitogen-stimulated c-rel2/2 B cells stained for pro-
tein and DNA content (Fig. 5 B). c-rel2/2 cells treated
with anti-RP antibody alone fail to progress to G1, whereas
a significant proportion of anti-RP antibody plus cytokine-
stimulated c-rel2/2 B cells can progress via G1 into S phase
and G2/M (Fig. 5 B). These results demonstrate that
c-rel2/2 and nfkb12/2 B cells are blocked at a point early
in G1 that precedes increased RNA and protein synthesis
and that cytokines can partly overcome this cell cycle block
allowing c-rel2/2 cells to progress through S plus G2/M.
Expression of a bcl-2 Transgene Inhibits Apoptosis but Does
Not Overcome the Cell Cycle Defect. To further understand
the mechanism(s) by which Rel and NF-kB1 prevent apop-
tosis in B lymphocytes, we tested whether the expression of
a bcl-2 transgene could inhibit the apoptosis of c-rel2/2 and
nfkb12/2 B cells. Survival curves for nonstimulated normal,
c-rel2/2, and nfkb12/2 B cells expressing bcl-2 (Fig. 6 A)
show that in addition to inhibiting the death of normal
quiescent B cells, a finding consistent with previous reports
(39), bcl-2 prevented the enhanced apoptosis of resting
nfkb12/2 B cells. Analysis of apoptosis and cell division in
mitogen-stimulated c-rel1/1bcl-21 and c-rel2/2bcl-21 B cell
cultures reveals that bcl-2 also prevented the death of anti-
IgM– and anti-RP–treated c-rel2/2 B cells (Fig. 6 C), but
failed to promote cell division (Fig. 6, B and D). Collec-
tively, these findings show that the death of B cells resulting
from an absence of Rel or NF-kB1 belong to that class of
apoptosis that can be inhibited by bcl-2.
c-myc Expression Is Normal in Mitogen-stimulated c-rel2/2
and nfkb12/2 B Cells. Recent studies have shown that
anti-IgM antibody-induced apoptosis in W231 B lym-
phoma cells appears to result from an inhibition of Rel/
NF-kB–mediated c-myc transcription (40, 41). To deter-
mine if the loss of Rel or NF-kB1 alters c-myc expression
in primary B cells, the level of c-myc mRNA in normal,
c-rel2/2, and nfkb12/2 B cells before and after stimulation
with anti-IgM antibodies was examined by Northern blot
analysis (Fig. 7). Consistent with previous findings (42), c-myc
mRNA levels are upregulated in normal B cells within 2 h
of stimulation (lane 5) and remain elevated after 4 h (lane 9).
In anti-IgM antibody stimulated W231 cells, an initial in-
crease in induced c-myc expression (1 h) is followed by a
downregulation of c-myc mRNA to near prestimulation
levels by 3 h (40). In contrast, c-myc mRNA levels were
upregulated normally in anti-IgM antibody-activated c-rel2/2
(lanes 6 and 10) and nfkb12/2 (lanes 7 and 11) B cells. Fur-
thermore, expression of a bcl-2 transgene, which reduces
anti-IgM antibody-induced apoptosis in c-rel2/2 B cells,
did not alter the pattern of c-myc expression (lanes 8 and
12). These results establish that neither Rel nor NF-kB1
alone is essential for anti-IgM–induced c-myc expression in
primary B lymphocytes and that the cell cycle block and
enhanced apoptosis in mitogen-activated c-rel2/2 B cells is
not a consequence of reduced c-myc expression.
The c-rel2/2 B Cell Proliferative Defect Is Partially Overcome
by Certain Combinations of Mitogens and Cytokines. Despite
the inability of c-rel2/2 B cells to proliferate in vitro in re-
sponse to a range of discrete mitogens, humoral responses
are reduced but not abrogated in c-rel2/2 mice (3; data not
Figure 4. Mitogen stimulation of c-rel2/2 B cells leads to changes in
cell size and the expression of certain cell surface markers. Normal and
Rel2/2 splenic B cells in the resting state (T 0), treated with anti-IgM, or
treated with anti-CD40 antibodies for 24 h were stained with biotinylated
monoclonal antibodies specific for class II MHC, B7.2, and the IL-2Ra
chain (CD25) and examined by flow cytometry. FSC, the forward light
scatter profiles (x-axis: log scale), is a measure of cell size. The vertical
lines shown in the class II MHC panels depict the fluorescence intensity
of cells stained with a biotinylated isotype-matched control antibody.
Data shown are electronically gated to exclude dead cells and are repre-
sentative of three experiments.669 Grumont et al.
shown). Since B cells are normally activated by multiple
signals during an immune response (43, 44), we examined
the proliferative response of c-rel2/2 B cells to a range of
mitogen and cytokine combinations. Table 1 summarizes
these results as the amount of [3H]thymidine incorporated
72 h after stimulation. In contrast to single stimuli, certain
combinations of mitogens or mitogens plus cytokines could
partially overcome the c-rel2/2 B cell proliferative defect.
For example, anti-IgM antibody plus LPS or anti-RP anti-
body plus LPS synergistically enhanced c-rel2/2 B cell pro-
liferation, whereas anti-RP plus anti-IgM antibodies failed
to augment the response above the level achieved by either
of the single mitogens. IL-4 increases anti-RP antibody-
induced c-rel2/2 B cell proliferation z70-fold, yet this
cytokine increases the response to LPS only marginally
(two- to threefold). Consistent with previous findings (3),
the proliferation of c-rel1/2 B cells in response to the panel
of single and multiple stimuli is intermediate between that
of normal and c-rel2/2 B cells (Table 1). Based on these re-
sults, B cell mitogens can be categorized into two groups:
those which do or do not cooperate to promote cellular
proliferation in the absence of Rel.
Figure 5. The cell cycle block in mitogen-activated c-rel2/2 and nfkb12/2
B cells occurs during the early phase of G1. (A) RNA synthesis is inhibited
in mitogen-treated c-rel2/2 and nfkb12/2 B cells. RNA synthesis in normal
(triangles), c-rel2/2 (circles), and nfkb12/2 (squares) B cells stimulated for 72 h
with either anti-IgM antibody, LPS, or anti-RP antibody in the absence
(open symbols) or presence (closed symbols) of cytokines was measured by
[3H]uridine incorporation. These results represent the mean of four experi-
ments 6SD. (B). The cell cycle block resulting from an absence of Rel pre-
vents B cells entering G1. B cells stimulated over a 72-h period with anti-
RP antibodies or anti-RP antibodies plus cytokines were analyzed by
simultaneous flow cytometry for DNA and protein content at 24-h inter-
vals. Data is presented as contour plots of DNA content (y-axis) versus pro-
tein content (x-axis). The percentage of viable cells in G0 for each series of
stimulations is indicated. Dead cells were excluded from analysis by elec-
tronic gating on forward and side scatter.670 Regulation of Apoptosis and Cell Division in B Cells by Rel/NF-kB
Discussion
We have demonstrated that Rel and NF-kB1, subunits
of the Rel/NF-kB family of transcription factors, differen-
tially regulate cell cycle progression and apoptosis in B lym-
phocytes. NF-kB1 prevents apoptosis in quiescent cells,
whereas both Rel and NF-kB1 are important for the sur-
vival of mitogen-activated B cells. Differences in the prolif-
erative defects exhibited by B cells lacking Rel or NF-kB1
also indicate that the requirement of one or both of these
transcription factors for progression through the G1 phase
of the cell cycle is dependent on the particular mitogenic
signal.
Different NF-kB–like Proteins Are Required for the B Cell
Proliferative Response to Specific Mitogens. Although both Rel
and NF-kB1 are required for normal B cell proliferation
(3–5) and Rel/NF-kB1 is the predominant NF-kB–like
heterodimer in splenic B lymphocytes (45–47), the induc-
tion of B cell mitogenesis by specific stimuli appears to re-
quire different NF-kB–like complexes. This is most clearly
illustrated for anti-IgM antibody-stimulated c-rel2/2 and
nfkb12/2 B cells. Anti-IgM antibody-activated nfkb12/2 B
cells proliferate normally despite Rel/RelA heterodimers
and Rel homodimers being the only NF-kB–like factors
Figure 6. Bcl-2 inhibits apoptosis of mitogen-stimulated c-rel2/2 B
cells, but fails to overcome the cell cycle block. (A) Bcl-2 inhibits the en-
hanced apoptosis of nfkb12/2 B cells. Quiescent splenic B cells isolated
from c-rel1/1bcl-21 (triangles), c-rel2/2bcl-21 (circles), and nfkb12/2bcl-
21 (squares) mice were cultured in DMEM/10% FCS without mitogen
for a period of 72 h. At 24-h intervals, the frequency of dead cells was de-
termined by trypan blue exclusion and by flow cytometric analysis of
fixed cells stained with PI. (B) Proliferation of c-rel2/2bcl-21 cells is im-
paired. The proliferation of c-rel1/1bcl-21 (triangles) and c-rel2/2bcl-21
(circles) B cells stimulated with either anti-IgM or anti-RP in the absence
(open symbols) or presence (closed symbols) of cytokines was monitored at
24-h intervals over a 72-h period by [3H]thymidine incorporation. (C)
Mitogen-induced death of c-rel2/2 cells is rescued by bcl-2. The fre-
quency of apoptotic cells in the mitogen-stimulated c-rel1/1bcl-21 and
c-rel2/2bcl-21 B cell cultures (symbols as for B) was determined by flow
cytometric analysis of PI-stained cells. The frequency of apoptotic cells is
presented as a proportion of the total cell number. Greater than 99% of
resting B cells of both genotypes were viable before mitogen stimulation.
(D) Cell cycle progression of mitogen-stimulated c-rel2/2bcl-21 cells re-
mains blocked. The DNA content of mitogen-stimulated c-rel1/1bcl-21
and c-rel2/2bcl-21 B cells (symbols as in B) was determined by flow cyto-
metric analysis of PI-stained cells. The fraction of viable B cells in S, G2,
or M is expressed as a function of the stimulation period. Less than 1% of
viable cells were in G1, S, or G2/M before stimulation. The results
shown represent the mean and SD from four experiments.
Figure 7. c-myc expression is normal in c-rel2/2 B cells. 10-mg sam-
ples of total RNA isolated from resting (lanes 1–4) and anti-IgM anti-
body-stimulated splenic B cells from normal, c-rel2/2, nfkb12/2, and
c-rel2/2bcl-21 mice stimulated for 2 h (lanes 5–8) and 4 h (lanes 9–12)
were fractionated on formaldehyde denaturing gels, transferred to nitro-
cellulose membranes, and sequentially hybridized with radiolabeled mu-
rine c-myc cDNA (32) or glyceraldehyde-3-phosphate-dehydrogenase
cDNA (33) probes. Filters were exposed for 48-h autoradiography at
2708C. Lanes 1, 5, and 9, normal B cells; 2, 6, and 10, Rel2/2 B cells; 3,
7, and 11, nfkb12/2 B cells; and 4, 8, and 12, c-rel2/2bcl-21 B cells. 
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upregulated in the nucleus (4; Grumont, R.J., results not
shown). In contrast, c-rel
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/
 
2
 
 B cells stimulated with this
mitogen fail to proliferate, even though nuclear NF-
 
k
 
B1/
RelA heterodimers and NF-
 
k
 
B1 homodimers are upregu-
lated with normal kinetics (3). Taking into consideration
the recent finding that proliferation of anti-IgM antibody-
stimulated rela
 
2
 
/
 
2
 
 B cells is also impaired (48), this indi-
cates that B cell mitogenesis triggered by engaging the anti-
gen receptor only requires Rel/RelA heterodimers and
Rel homodimers. LPS-dependent B cell proliferation,
however requires Rel, RelA, and NF-
 
k
 
B1 (3, 4, 48).
Certain mitogen combinations such as anti-IgM anti-
body and LPS, anti-RP antibody and LPS, or anti-RP anti-
body plus cytokines synergistically enhance B cell prolifera-
tion by increasing cell division and reducing apoptosis,
whereas others such as anti-IgM and anti-RP antibodies fail
to increase c-rel
 
2
 
/
 
2
 
 B cell mitogenesis above that pro-
moted by the individual stimuli. These findings are consis-
tent with models in which dual stimuli partly overcome the
proliferative defect as a result of each mitogen activating
distinct intracellular signals required for survival and/or cell
cycle progression. Conversely, it would appear that non-
synergizing mitogens such as anti-IgM plus anti-RP anti-
bodies engage the same or functionally equivalent signaling
pathways. If Rel controls a single pathway crucial for the
division and survival of B cells, then perhaps multiple mito-
gens can in part bypass the need for Rel by engaging the
pathway downstream of Rel. The molecular basis of mito-
gen synergy remains to be determined. This could involve
activation of other NF-
 
k
 
B–like complexes, or Rel/NF-
 
k
 
B–independent signal transduction pathways. The second
possibility is consistent with the finding that mitogen-acti-
vated protein (MAP) and stress-activated protein (SAP) ki-
nases are activated normally in c-rel
 
2
 
/
 
2
 
 B (results not
shown).
 
In B Cells, Rel and NF-
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B1 Regulate G1 Cell Cycle Pro-
gression.
 
c-rel
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 and nfkb1
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/
 
2
 
 B cells undergo abortive
mitogenic responses characterized by initial cell enlarge-
ment but failure to undergo RNA and protein synthesis.
This indicates that cell cycle arrest occurs at a stage be-
tween early and late G1. Consistent with Rel and NF-
 
k
 
B1
controlling cell cycle progression is the recent finding that
the cyclin-dependent kinase Cdk2 can regulate the tran-
scriptional activation of RelA through mutual interaction
with the coactivator p300 (49). Our data also shows that
the involvement of particular Rel/NF-
 
k
 
B subunits in cell
cycle regulation may be cell-type specific. Although NF-
 
k
 
B1 is important for B cell division and NF-
 
k
 
B (NF-
 
k
 
B1/
RelA) is induced in fibroblasts during the G0 to G1 transi-
tion (50), mitogen-stimulated primary fibroblasts that lack
NF-
 
k
 
B1 divide normally (Gerondakis, S., unpublished re-
sults).
The synergistic action of mitogen combinations in pro-
moting c-rel
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/
 
2
 
 B cell proliferation (e.g., anti-RP antibod-
ies plus cytokines) demonstrates certain signals permit near
normal numbers of c-rel
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/
 
2
 
 B cells to progress through G1
and complete the cell cycle. Although this indicates that
neither Rel nor NF-
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B1 appear to be essential at other
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stages of the cell cycle, it remains a possibility that a re-
quirement for these transcription factors at a post-G1 stage
of the cell cycle could also be overcome by certain mito-
genic signals. Despite dual stimuli increasing the frequency
of dividing c-rel2/2 cells, an inability to completely bypass
the Rel-dependent phase in G1 is consistent with only a
subset of splenic B cells responding to the combined stimu-
lus. If true, this would indicate heterogeneity in the control
of cell division amongst primary splenic B cells.
Rel and NF-kB1 Are Important for Survival of Quiescent and
Mitogen-activated B Cells. Our results demonstrate for the
first time that NF-kB1, like Rel and RelA, is important in
regulating cell survival. In normal B lymphocytes, NF-kB1
is required for the survival of quiescent cells, whereas both
Rel and NF-kB1 prevent apoptosis after mitogenic stimu-
lation. Data from a variety of experimental systems indicate
that Rel/NF-kB–like transcription factors can play both
anti- (21–24, 40, 41, this paper) and proapoptotic (25, 51,
52) roles. Such a dual function for particular Rel/NF-kB–
like factors may depend on the cell type and the nature of
the apoptotic signal. For example, the importance of cell
type is emphasized with NF-kB1 protecting resting and
LPS-treated B cells from apoptosis (this paper) while being
dispensible for survival of TNF-a–treated embryonic fibro-
blasts (21). Quantitative differences in the survival of
c-rel2/2 and nfkb12/2 B cells treated with different mito-
gens also emphasizes the complex relationship between
Rel/NF-kB–dependent mitogenesis and apoptosis.
It remains to be determined how Rel and NF-kB1 pro-
mote the survival of B lymphocytes and which gene(s) cru-
cial to cell survival are regulated by these transcription fac-
tors in quiescent and mitogen-stimulated cells. Since Rel
and NF-kB1 can function both as a transcriptional activa-
tors or repressors (4, 19, 20), cell survival mediated by these
proteins could result either from the induction of a survival
gene or repression of a cell death gene. Candidate gene(s)
include those specifically dedicated to controlling cell sur-
vival, or in the case of mitogen-stimulated c-rel2/2 and
nfkb12/2 B cells, these could be cell cycle genes if en-
hanced levels of death are an indirect consequence of the
impaired expression of genes required for G1 progression.
Support for the former model comes from the finding that
even though mitogen-induced rela2/2 B cell proliferation
is impaired, apoptosis is normal (48), suggesting that the
defects in mitogen-treated c-rel2/2 and nfkb12/2 B cells
could be the result of Rel and NF-kB1 regulating two dis-
tinct groups of genes, one crucial for cell cycle progression
and the other apoptosis. Moreover, it appears likely that
Rel/NF-kB factors regulate the expression of more than
one gene important for lymphocyte survival. Although
c-myc is a crucial regulator of cell division and apoptosis
(53) and anti-IgM–treated W231 B lymphoma cells un-
dergo apoptosis due an inhibition of Rel/NF-kB–depen-
dent c-myc transcription (40, 41), the expression of c-myc
was normal in quiescent or anti-IgM–treated c-rel2/2 and
nfkb12/2 B cells. This difference may indicate that the reg-
ulation of c-myc transcription differs in primary and im-
mortalized B cells. NF-kB–induced cellular inhibitor of
apoptosis protein 2 (c-IAP2) expression was also shown to
be important in preventing the TNF-a–mediated death of
Jurkat T cells (54), yet the absence of Rel or NF-kB1 does
not alter c-IAP2 expression in B cells (results not shown).
Ultimately, the identification of Rel/NF-kB–regulated
genes in B cells that are important for cell cycle regulation
and cell survival should offer important insight into the
mechanisms by which different Rel/NF-kB dimers regulate
these processes in response to particular mitogenic signals.
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